Emergent BioSolutions

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 1.6K

Market Cap: -

Website

Introduction: Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Clinical Trials

A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients

Not yet recruiting

Conditions: Inhalational Anthrax

Interventions: Drug: AIGIV

First Posted Date: 2018-06-26

Last Posted Date: 2025-01-15

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 100

Registration Number: NCT03569553

Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

Phase 2

Completed

Conditions: Influenza A H3N2
Influenza A H1N1

Interventions: Biological: FLU-IGIV
Other: Placebo for FLU-IGIV

First Posted Date: 2017-10-19

Last Posted Date: 2024-03-18

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 65

Registration Number: NCT03315104

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Michael E. DeBakey VA Medical Center, Houston, Texas, United States

and more 52 locations

A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047

Phase 1

Terminated

Conditions: Adenoviral Infection

Interventions: Biological: Teva Ad4/Ad7 Vaccine
Biological: PXVX0047 Vaccine

First Posted Date: 2017-05-19

Last Posted Date: 2024-03-18

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 25

Registration Number: NCT03160339

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
University of Vermont Medical Center, Burlington, Vermont, United States

Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults

Phase 1

Terminated

Conditions: Healthy Volunteer
HIV Vaccine

Interventions: Biological: Ad4-mgag
Other: Placebo Comparator
Biological: AIDSVAX B/E
Biological: Ad4-EnvC150

First Posted Date: 2016-05-13

Last Posted Date: 2024-03-18

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 20

Registration Number: NCT02771730

Locations: 🇺🇸
Paxvax, Redwood City, California, United States

Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects

Phase 1

Terminated

Conditions: Viral Infection

Interventions: Drug: UV-4B 75 mg oral solution
Drug: UV-4B Y mg (dose to be determined) oral solution
Drug: UV-4B X mg (dose to be determined) oral solution
Drug: UV-4B 150 mg oral solution
Drug: UV-4B 30 mg oral solution
Drug: Placebo

First Posted Date: 2016-03-02

Last Posted Date: 2024-03-18

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 7

Registration Number: NCT02696291

Locations: 🇺🇸
Clinical Research Unit, Madison, Wisconsin, United States

VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV

Phase 4

Completed

Conditions: Smallpox Vaccine Adverse Reaction

Interventions: Biological: Vaccination with ACAM2000

First Posted Date: 2015-05-14

Last Posted Date: 2024-03-18

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 3032

Registration Number: NCT02443623

Locations: 🇨🇦
Bio Products Laboratory Ltd (plasma vendor of Emergent BioSolutions), Winnipeg, Manitoba, Canada

Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed

Phase 4

Completed

Conditions: Infections, Bacterial

Interventions: Biological: AVA
Biological: Raxibacumab
Drug: Diphenhydramine

First Posted Date: 2015-01-15

Last Posted Date: 2024-03-18

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 573

Registration Number: NCT02339155

Locations: 🇺🇸
GSK Investigational Site, Knoxville, Tennessee, United States

Clinical Benefit, Safety and PK of Raxibacumab in Subjects Exposed to Bacillus Anthracis

Phase 4

Not yet recruiting

Conditions: Infections, Bacterial

Interventions: Biological: Collection of samples

First Posted Date: 2014-06-30

Last Posted Date: 2020-10-05

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 100

Registration Number: NCT02177721

Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects

Phase 1

Completed

Conditions: Viral Infection

Interventions: Drug: UV-4B 720 mg
Drug: UV-4B 1000 mg
Drug: UV-4B 3 mg
Drug: UV-4B 30 mg
Drug: UV-4B 90 mg
Drug: UV-4B 10 mg
Drug: UV-4B 180 mg
Drug: UV-4B 360 mg
Drug: Placebo

First Posted Date: 2014-02-12

Last Posted Date: 2024-03-18

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 64

Registration Number: NCT02061358

Locations: 🇺🇸
Quintiles, Inc, Overland Park, Kansas, United States

BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin

Completed

Conditions: Botulism

Interventions: Drug: BAT

First Posted Date: 2014-02-05

Last Posted Date: 2024-03-15

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 162

Registration Number: NCT02055183

Home Terms & Conditions Privacy Policy